Key facts
- It has raised $2.6M; the latest was Seed Round ($2.0M) in Sep 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Arena Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Arena Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arena Therapeutics
Provider of brain modulation therapy intended to treat all stages of Parkinson's disease by targeting disease progression, not just symptom management. The company offers a novel stimulation approach using a patent-pending implantable system with precise software-guided targeting, enabling patients with early- to late-stage Parkinson's disease improved outcomes, reduced side effects, and greater treatment durability.
- Sector
- Healthcare
- HQ
- Blaine, MN, United States
- Founded
- 2024
- Website
- arenatherapeutics.com/
- Ownership
- Privately Held (backing)
Arena Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arena Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arena Therapeutics in its N-PORT filings yet. We sweep new filings monthly.